Glyco-therapy Biotechnology Co., Ltd. owns the proprietary glyco-editing-based site-specific conjugation platform YTConju™. The platform employs engineered fucosyltransferase to site-specifically modify glycosylation at conserved positions in the Fc region. Using a "one-pot" aqueous reaction system, it efficiently constructs homogeneous and stable antibody-drug conjugates (ADCs). The YTConju™ platform supports precise design for various drug-to-antibody ratios (DARs), including DAR2, DAR4, DAR2*2, DAR4*2, DAR2+2, DAR4+2, and DAR4+4, as well as the construction of multiple payloads such as cytotoxin, immunostimulator, peptides, proteins and oligonucleotides on different types of antibodies (monoclonal antibodies, bispecific antibodies, Fc fusion proteins, etc.).

Unlike traditional site-specific conjugation strategies, YTConju™ eliminates the need for genetic re-engineering of antibodies, enabling high-throughput and efficient conjugation preparation. Furthermore, the platform uses a single conjugation substrate to construct ADCs with different DAR values, typically resulting in highly uniform, hydrophilic, and stable conjugates. Compared to conventional approaches, the YTConju™ platform expands the scope and depth of ADC development, accelerating the drug development process.

The YTConju™ platform enables the precise design and construction of various small molecule drugs (cytotoxin, immunostimulator, etc.) with different drug-to-antibody ratios (DARs), including DAR2, DAR4, DAR2+2, DAR4+2, and DAR4+4, on a wide range of antibodies, including monoclonal antibodies, bispecific antibodies, and Fc fusion proteins. The resulting conjugates typically exhibit high homogeneity, high hydrophilicity, low aggregation, excellent plasma stability, and superior thermal stability, along with outstanding efficacy in both in vitro and in vivo settings.

The YTConju™ platform facilitates the efficient conjugation of antibodies with oligonucleotides of various sizes, producing homogenous and stable conjugates.

The YTConju™ platform enables the efficient conjugation of various peptides and proteins (such as peptides, nanobodies, enzymes, and cytokines) with antibodies, resulting in homogeneous and stable conjugates.